News Release

November 15, 2021

Change of Marketing Scheme for "RECTABUL®2mg Rectal Foam 14 Doses" and AJM300 (Nonproprietary Name: Carotegrast Methyl), Both for Treatment of Ulcerative Colitis - Agreement Concluded

September 27, 2021

Marketing Authorization Approval in Japan for TAVNEOS® Capsules 10mg, a selective Complement C5a Receptor Antagonist

September 15, 2021

New Drug Application submitted to U.S. FDA for Linzagolix for the treatment of uterine fibroids

September 2, 2021

Licensing Agreement for GnRH Antagonist Linzagolix with Bio Genuine in China

August 19, 2021

Launch of UPASITA® IV Injection Syringe for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients

August 5, 2021

Sub-licensing Agreement for Spleen Tyrosine Kinase Inhibitor Fostamatinib with Inmagene Biopharmaceuticals

July 1, 2021

Phase III Clinical Study Data of AJM300 (Nonproprietary Name: Carotegrast Methyl) Conducted in Japan for Treatment of Ulcerative Colitis (AJM300/CT3 Study) will be presented in the 16th Congress of European Crohn's and Colitis Organisation (ECCO'21)

June 28, 2021

Sub-licensing Agreement for Spleen Tyrosine Kinase Inhibitor "Fostamatinib (R788)" with JW Pharmaceutical Corporation

June 23, 2021

Announcement of Marketing Authorization Approval in Japan and Co-promotion Agreement of UPASITA® IV Injection Syringe for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients

May 28, 2021

EA Pharma Filed Marketing Approval Application for AJM300 (Nonproprietary Name: Carotegrast Methyl) Indicated for Treatment of Ulcerative Colitis

March 24, 2021

Participation in global Phase III clinical trial for CG0070, a drug for bladder cancer

March 1, 2021

Submission of New Drug Application for Avacopan (CCX168), a Complement C5a Receptor Inhibitor, in Japan

January 13, 2021

Results of Phase III Clinical Study of AJM300 (Nonproprietary Name: Carotegrast Methyl) for Treatment of Ulcerative Colitis Conducted in Japan (AJM300/CT3 Study) - Primary Endpoint Achieved -